Syros Capital Stock from 2010 to 2025

SYRS Stock

USD 0.18 0.01 3.06%

Syros Pharmaceuticals Capital Stock yearly trend continues to be comparatively stable with very little volatility. Capital Stock is likely to outpace its year average in 2025. Capital Stock is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. View All Fundamentals

Capital Stock

First Reported

2010-12-31

Previous Quarter

23.4 K

Current Value

32 K

Quarterly Volatility

10.4 K

Credit Downgrade

Yuan Drop

Covid

Check Syros Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Syros Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.1 M, Interest Expense of 6.2 M or Selling General Administrative of 18.9 M, as well as many indicators such as Price To Sales Ratio of 24.26, Dividend Yield of 0.0 or PTB Ratio of 12.51. Syros financial statements analysis is a perfect complement when working with Syros Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Syros Pharmaceuticals Correlation against competitors.

For more information on how to buy Syros Stock please use our How to Invest in Syros Pharmaceuticals guide.

Latest Syros Pharmaceuticals' Capital Stock Growth Pattern

Below is the plot of the Capital Stock of Syros Pharmaceuticals over the last few years. It is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. Syros Pharmaceuticals' Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Syros Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

Capital Stock

10 Years Trend

Very volatile

Compare to Others All Fundamentals

Capital Stock

Timeline

Syros Capital Stock Regression Statistics

	Arithmetic Mean	35,462
	Geometric Mean	34,182
	Coefficient Of Variation	29.45
	Mean Deviation	6,702
	Median	34,000
	Standard Deviation	10,444
	Sample Variance	109.1M
	Range	41K
	R-Value	(0.04)
	Mean Square Error	116.7M
	R-Squared	0
	Significance	0.89
	Slope	(82.06)
	Total Sum of Squares	1.6B

Syros Capital Stock History

	2025	32 K
	2024	23.4 K
	2023	26 K
	2022	20 K
	2021	61 K
	2020	56 K
	2019	43 K

Other Fundumenentals of Syros Pharmaceuticals

Issuance Of Capital Stock

Syros Pharmaceuticals Capital Stock component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Short Term Investments	Total Liab	Deferred Long Term Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Long Term Debt Total	Capital Surpluse	Current Deferred Revenue	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.28	0.87	-0.47	-0.86	0.59	0.89	0.0	-0.26	0.85	0.21	0.87	0.99	0.67	0.73	0.68	0.85	0.88	0.81	0.76	0.95	0.1
Total Stockholder Equity	0.28		-0.01	-0.12	0.19	-0.53	0.2	0.22	0.59	-0.25	-0.01	0.0	0.28	-0.49	0.24	0.16	-0.14	-0.09	0.18	0.61	0.27	0.3
Net Tangible Assets	0.87	-0.01		-0.37	-0.93	0.78	0.78	0.12	-0.35	0.91	-0.14	0.87	0.88	0.81	0.74	0.58	0.84	0.96	0.68	0.53	0.8	-0.05
Net Debt	-0.47	-0.12	-0.37		0.37	-0.24	-0.22	0.53	0.64	-0.43	-0.13	-0.26	-0.56	-0.39	0.02	0.24	-0.53	-0.31	-0.24	-0.46	-0.63	0.28
Retained Earnings	-0.86	0.19	-0.93	0.37		-0.88	-0.8	0.04	0.45	-0.97	-0.11	-0.89	-0.86	-0.92	-0.62	-0.59	-0.92	-0.98	-0.67	-0.49	-0.81	0.11
Accounts Payable	0.59	-0.53	0.78	-0.24	-0.88		0.56	-0.08	-0.56	0.9	0.07	0.75	0.59	0.94	0.37	0.43	0.77	0.84	0.41	0.19	0.59	-0.33
Long Term Debt	0.89	0.2	0.78	-0.22	-0.8	0.56		0.26	-0.05	0.76	0.07	0.95	0.87	0.57	0.79	0.74	0.7	0.81	0.76	0.59	0.8	0.19
Net Receivables	0.0	0.22	0.12	0.53	0.04	-0.08	0.26		0.65	-0.12	-0.56	0.18	-0.02	-0.26	0.36	0.28	-0.31	0.01	0.03	-0.09	-0.11	0.12
Short Term Investments	-0.26	0.59	-0.35	0.64	0.45	-0.56	-0.05	0.65		-0.58	-0.28	-0.22	-0.29	-0.69	0.0	0.11	-0.6	-0.37	-0.28	0.01	-0.33	0.16
Total Liab	0.85	-0.25	0.91	-0.43	-0.97	0.9	0.76	-0.12	-0.58		0.15	0.89	0.84	0.95	0.62	0.59	0.95	0.96	0.73	0.5	0.83	-0.05
Deferred Long Term Liab	0.21	-0.01	-0.14	-0.13	-0.11	0.07	0.07	-0.56	-0.28	0.15		0.0	0.15	0.11	-0.08	0.31	0.23	0.03	0.23	0.17	0.22	0.15
Short Long Term Debt	0.87	0.0	0.87	-0.26	-0.89	0.75	0.95	0.18	-0.22	0.89	0.0		0.85	0.75	0.77	0.72	0.8	0.91	0.77	0.57	0.81	0.11
Total Current Assets	0.99	0.28	0.88	-0.56	-0.86	0.59	0.87	-0.02	-0.29	0.84	0.15	0.85		0.67	0.67	0.58	0.85	0.87	0.75	0.75	0.96	0.01
Short Term Debt	0.67	-0.49	0.81	-0.39	-0.92	0.94	0.57	-0.26	-0.69	0.95	0.11	0.75	0.67		0.41	0.41	0.9	0.88	0.53	0.28	0.65	-0.21
Common Stock	0.73	0.24	0.74	0.02	-0.62	0.37	0.79	0.36	0.0	0.62	-0.08	0.77	0.67	0.41		0.8	0.58	0.71	0.89	0.53	0.57	0.59
Property Plant Equipment	0.68	0.16	0.58	0.24	-0.59	0.43	0.74	0.28	0.11	0.59	0.31	0.72	0.58	0.41	0.8		0.5	0.65	0.76	0.46	0.51	0.48
Long Term Debt Total	0.85	-0.14	0.84	-0.53	-0.92	0.77	0.7	-0.31	-0.6	0.95	0.23	0.8	0.85	0.9	0.58	0.5		0.92	0.75	0.62	0.85	0.03
Capital Surpluse	0.88	-0.09	0.96	-0.31	-0.98	0.84	0.81	0.01	-0.37	0.96	0.03	0.91	0.87	0.88	0.71	0.65	0.92		0.73	0.57	0.82	-0.01
Current Deferred Revenue	0.81	0.18	0.68	-0.24	-0.67	0.41	0.76	0.03	-0.28	0.73	0.23	0.77	0.75	0.53	0.89	0.76	0.75	0.73		0.67	0.73	0.61
Net Invested Capital	0.76	0.61	0.53	-0.46	-0.49	0.19	0.59	-0.09	0.01	0.5	0.17	0.57	0.75	0.28	0.53	0.46	0.62	0.57	0.67		0.83	0.25
Net Working Capital	0.95	0.27	0.8	-0.63	-0.81	0.59	0.8	-0.11	-0.33	0.83	0.22	0.81	0.96	0.65	0.57	0.51	0.85	0.82	0.73	0.83		-0.02
Capital Stock	0.1	0.3	-0.05	0.28	0.11	-0.33	0.19	0.12	0.16	-0.05	0.15	0.11	0.01	-0.21	0.59	0.48	0.03	-0.01	0.61	0.25	-0.02

Click cells to compare fundamentals

About Syros Pharmaceuticals Financial Statements

Syros Pharmaceuticals shareholders use historical fundamental indicators, such as Capital Stock, to determine how well the company is positioned to perform in the future. Although Syros Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Syros Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Syros Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Capital Stock	23.4 K	32 K
Issuance Of Capital Stock	49.8 M	86.2 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Syros Stock Analysis

When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Syros Capital Stock from 2010 to 2025

Latest Syros Pharmaceuticals' Capital Stock Growth Pattern

Syros Capital Stock Regression Statistics

Syros Capital Stock History

Other Fundumenentals of Syros Pharmaceuticals

Syros Pharmaceuticals Capital Stock component correlations

About Syros Pharmaceuticals Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Syros Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY